Lead Product(s): MVA-BN Filo vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: MVA-BN-Filo
Highest Development Status: Phase III Product Type: Vaccine
Partner/Sponsor/Collaborator: Janssen Pharmaceutical
Deal Size: $13.9 million Upfront Cash: Undisclosed
Deal Type: Agreement June 18, 2020
Bavarian Nordic will manufacture and deliver bulk drug substance of its MVA-BN Filo vaccine, which Janssen has licensed as part of its Ebola vaccine regimen.